Molly Henderson
2023 - Phathom Pharmaceuticals
In 2023, Molly Henderson earned a total compensation of $1.9M as Chief Financial and Business Officer at Phathom Pharmaceuticals, a 29% decrease compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $260,888 |
---|---|
Option Awards | $281,105 |
Salary | $500,000 |
Stock Awards | $814,925 |
Other | $16,875 |
Total | $1,873,793 |
Henderson received $814.9K in stock awards, accounting for 43% of the total pay in 2023.
Henderson also received $260.9K in non-equity incentive plan, $281.1K in option awards, $500K in salary and $16.9K in other compensation.
Rankings
In 2023, Molly Henderson's compensation ranked 564th out of 2,785 executives tracked by ExecPay. In other words, Henderson earned more than 79.7% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 564 | 80th |
Manufacturing | 322 | 79th |
Chemicals And Allied Products | 226 | 74th |
Drugs | 223 | 73rd |
Pharmaceutical Preparations | 139 | 77th |
Henderson's colleagues
We found two more compensation records of executives who worked with Molly Henderson at Phathom Pharmaceuticals in 2023.
News
Phathom Pharmaceuticals CEO Terrie Curran's 2023 pay falls 32% to $3.4M
April 12, 2024
Phathom Pharmaceuticals CEO Terrie Curran's 2022 pay slips 20% to $5M
April 13, 2023
UroGen Pharma Ltd. CEO Elizabeth Barrett's 2020 pay falls 90% to $2.5M
April 28, 2021
Advaxis CEO Kenneth Berlin's 2020 pay jumps 21% to $1.2M
April 21, 2021